News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
518,846 Results
Type
Article (44260)
Company Profile (131)
Press Release (474455)
Section
Business (144990)
Career Advice (2382)
Deals (27914)
Drug Delivery (107)
Drug Development (68036)
Employer Resources (149)
FDA (15557)
Job Trends (11933)
News (263763)
Policy (29590)
Tag
Academia (2285)
Alliances (35803)
Alzheimer's disease (1282)
Approvals (15465)
Artificial intelligence (121)
Bankruptcy (300)
Best Places to Work (9111)
Biotechnology (83)
Breast cancer (112)
Cancer (1030)
Cardiovascular disease (96)
Career advice (1989)
Cell therapy (232)
Clinical research (53905)
Collaboration (338)
Compensation (200)
COVID-19 (2544)
C-suite (90)
Data (1034)
Diabetes (151)
Diagnostics (5095)
Drug pricing (97)
Earnings (57239)
Employer resources (137)
Events (74974)
Executive appointments (267)
FDA (16083)
Funding (285)
Gene therapy (184)
GLP-1 (643)
Government (3802)
Healthcare (14707)
Infectious disease (2630)
Inflammatory bowel disease (101)
Interviews (445)
IPO (13805)
Job creations (3155)
Job search strategy (1660)
Layoffs (450)
Legal (6909)
Lung cancer (169)
Manufacturing (169)
Medical device (11055)
Medtech (11058)
Mergers & acquisitions (14172)
Metabolic disorders (436)
Neuroscience (1553)
NextGen Class of 2024 (4980)
Non-profit (3171)
Northern California (1348)
Obesity (257)
Opinion (189)
Patents (103)
People (41883)
Phase I (16078)
Phase II (23352)
Phase III (19182)
Pipeline (455)
Policy (86)
Postmarket research (2208)
Preclinical (6527)
Radiopharmaceuticals (202)
Rare diseases (221)
Real estate (4257)
Regulatory (20223)
Research institute (2053)
Resumes & cover letters (400)
Southern California (1150)
Startups (2744)
United States (11723)
Vaccines (618)
Weight loss (212)
Date
Today (118)
Last 7 days (657)
Last 30 days (3440)
Last 365 days (31678)
2024 (29095)
2023 (35058)
2022 (45137)
2021 (48566)
2020 (45571)
2019 (36299)
2018 (27445)
2017 (27860)
2016 (25880)
2015 (28086)
2014 (21857)
2013 (17855)
2012 (19040)
2011 (19443)
2010 (17580)
Location
Africa (668)
Arizona (138)
Asia (30585)
Australia (5356)
California (2939)
Canada (958)
China (188)
Colorado (128)
Connecticut (148)
Europe (74253)
Florida (418)
Georgia (99)
Illinois (265)
Indiana (152)
Maryland (532)
Massachusetts (2310)
Michigan (118)
Minnesota (216)
New Jersey (850)
New York (827)
North Carolina (641)
Northern California (1348)
Ohio (110)
Pennsylvania (739)
South America (1031)
Southern California (1150)
Texas (395)
Washington State (323)
518,846 Results for "alk abello a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
November 7, 2024
·
1 min read
Press Releases
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024
August 14, 2024
·
1 min read
FDA
ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis
October 7, 2024
·
3 min read
Business
Annual report 2023: ALK delivers 9% sales growth with profits up 50%
ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2023 annual report.
February 8, 2024
·
3 min read
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
Alkermes plc announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies, taking place June 1-5, 2024 in Houston.
May 28, 2024
·
5 min read
Press Releases
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
November 11, 2024
·
8 min read
Press Releases
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
November 11, 2024
·
10 min read
Press Releases
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
October 25, 2024
·
9 min read
Press Releases
ALK upgrades its full-year revenue and earnings outlook
August 26, 2024
·
2 min read
Drug Development
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes plc announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1.
April 24, 2024
·
5 min read
1 of 51,885
Next
